# Systemic anti-cancer therapy for advanced non-small-cell lung cancer

## Non-squamous non-small cell lung cancer, EGFR-TK positive

Initial recommended treatment options are:

* the [NICE technology appraisal guidance on afatinib](https://www.nice.org.uk/guidance/TA310) or
* the [NICE technology appraisal guidance on dacomitinib](https://www.nice.org.uk/guidance/TA595) or
* the [NICE technology appraisal guidance on erlotinib](https://www.nice.org.uk/guidance/TA258) or
* the [NICE technology appraisal guidance on gefitinib](https://www.nice.org.uk/guidance/TA192) or
* the [NICE technology appraisal guidance on osimertinib](https://www.nice.org.uk/guidance/TA654) or
* platinum doublet chemotherapy.

For people who have disease progression after initial treatment with platinum doublet chemotherapy, recommended treatment options are:

* the [NICE technology appraisal guidance on afatinib](https://www.nice.org.uk/guidance/TA310) or
* the [NICE technology appraisal guidance on erlotinib](https://www.nice.org.uk/guidance/TA374).

For people who are T970M positive and have disease progression after initial treatment in line with the [NICE technology appraisal guidance on afatinib](https://www.nice.org.uk/guidance/TA310), [dacomitinib](https://www.nice.org.uk/guidance/TA595), [erlotinib](https://www.nice.org.uk/guidance/TA258) or [gefitinib](https://www.nice.org.uk/guidance/TA192), the only recommended treatment option is the [NICE technology appraisal guidance on osimertinib](https://www.nice.org.uk/guidance/TA653).

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on afatinib](https://www.nice.org.uk/guidance/TA310), [dacomitinib](https://www.nice.org.uk/guidance/TA595), [erlotinib](https://www.nice.org.uk/guidance/TA258), [gefitinib](https://www.nice.org.uk/guidance/TA192) or [osimertinib](https://www.nice.org.uk/guidance/TA654), or after follow-up treatment with [osimertinib](https://www.nice.org.uk/guidance/TA653) (for people who are T970M positive), recommended treatment options are:

* platinum doublet chemotherapy or
* the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181) (NHS England policy) or
* pemetrexed and carboplatin or
* the [NICE technology appraisal guidance on atezolizumab and bevacizumab, carboplatin and paclitaxel](https://www.nice.org.uk/guidance/TA584).

For people who have disease progression after treatment in line with the [NICE technology appraisal guidance on atezolizumab and bevacizumab, carboplatin and paclitaxel](https://www.nice.org.uk/guidance/TA584), recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

For maintenance treatment for people who have had follow-up treatment with platinum doublet chemotherapy, the only recommended treatment option is the [NICE technology appraisal guidance on pemetrexed maintenance](https://www.nice.org.uk/guidance/ta190).

For maintenance treatment for people who have had follow-up treatment in line with the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), the only recommended treatment option is the [NICE technology appraisal guidance on pemetrexed maintenance](https://www.nice.org.uk/guidance/ta402).

Pemetrexed maintenance is a recommended maintenance treatment option for people who have had follow-up treatment with pemetrexed and carboplatin (NHS England policy).

For people who have disease progression after follow-up treatment with platinum doublet chemotherapy, the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), pemetrexed and carboplatin, or after pemetrexed maintenance, or after initial platinum doublet chemotherapy and follow-up treatment in line with the [NICE technology appraisal guidance on afatinib](https://www.nice.org.uk/guidance/TA310) or [erlotinib](https://www.nice.org.uk/guidance/TA374), recommended treatment options are:

* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428) (if PD‑L1 above 1%) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta520) (any PD-L1 0% to 100%) or
* the [NICE technology appraisal guidance on nivolumab](https://www.nice.org.uk/guidance/ta713) (if PD-L1 above 1%) or
* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

For people who have disease progression after treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428), [atezolizumab](https://www.nice.org.uk/guidance/ta520) or [nivolumab](https://www.nice.org.uk/guidance/ta713), recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).